Abstract:Objective: To observe the efficacy and safety of NPH versus premixed insulin combined with oral antidiabetic drugs in the treatment of newly diagnosed type 2 diabetic patients. Methods: The 128 newly diagnosed type 2 diabetic patients which FBG was at least 12 mmol/L or HbA1C at least 9.5%were randomly assigned to receive insulin NPH and OADs( repaglinide and metformin) or premixed insulin and OADs( acarbose and metformin),respectively ,for 12 weeks. Fasting blood glucose,2-hour past-meal blood glucose,blood hem-atoglobin A1C, waistline,hipline, body weight and the frequency of hypoglycemia were analyzed before and after the treatment . Results:After the 12-week of treatment ,the levels of FBG,2hPBG,and HbA1C of the two groups were decreased(P﹤0.01),while the decrease in the NPH group was more significant(P﹤0.01). the levels of FBG,2hPBG,and HbA1C were al decreased significantly in NPH group than those of baselines ,from (14.3±2.1) mmol/L,(18.6±3.8) mmol/L,(11.5±2.1)%to (6.3±1.1) mmol/L,(8.2±1.7) mmol/L,(6.6±1.6)%, respectively;al P﹤0.01. And those indicator were al significantly declined too in premixed insulin group, from (14.1±2.1) mmol/L,(18.4±3.7) mmol/L,(11.3±2.1)%to (7.1±1.7) mmol/L,(9.1±2.0) mmol/L,(7.7±1.3)%,respectively,and al P﹤0.01. The increase of body weight in NPH group(0.88kg) was inferior to premixed insulin group(1.84kg) (P﹤0.01).The doses of NPH(9±3.6)U/d was significantly lower than these of premixed insulin(17±3.3)U/d (P=0.0001).As HbAIC﹤7.0%for target, targeting of HbA1C in NPH group(87.5%)was superior to the premixed insulin group(73.4%)(P=0.045). The incidence of hypoglycemia in NPH group was inferior to the premixed insulin group(P=0.042). Conclusion: As compared with premixed insulin plus acarbose or metformin,the ef ect of insulin NPH and OADs( repaglinide and metformin) is bet er in newly diagnosed patients with less doses of insulin ,less incidence of hypoglycemia and less influence on body weight.